AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594054 |
Inflammation Digital Biomarkers Validation Study |
NOT_YET_RECRUITING | |
| NCT07592624 |
Evaluation of an Instructional Video About Medication Management During Admission and Medication Adherence for Kidney Transplantation and in the Outpatient Clinic in a Dutch University Hospital. |
NOT_YET_RECRUITING | NA |
| NCT07587918 |
Sweet & Sour: Dietary Acid Load in Type 2 Diabetes and Kidney Disease Across Sex and Ethnic Groups |
NOT_YET_RECRUITING | NA |
| NCT07583628 |
CMC-1 Replacement Arthroplasty Versus Trapeziectomy |
COMPLETED | |
| NCT07556887 |
Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation |
RECRUITING | NA |
| NCT07513077 |
Prevention of Noise-Induced Hearing Loss in Primary Education |
RECRUITING | NA |
| NCT07497724 |
Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC) |
ACTIVE_NOT_RECRUITING | |
| NCT07491328 |
Liquid Biopsy in Paraneoplastic Neurological Syndromes |
RECRUITING | |
| NCT07485452 |
Boosting Osimertinib Blood Brain Barrier Penetration |
NOT_YET_RECRUITING | PHASE2 |
| NCT07482124 |
Multicenter Registry of Patients With Subarachnoid Hemorrhage |
RECRUITING |
